The effects of intravenous elgodipine, a new second-generation dihydropyridtne calcium antagonist, on hemodynamics and coronary artery diameter were investigated in 15 patients undergoing cardiic catheterixation for suspected coronary artery disease. Despite a significant decrease in systemic blood pressure, elgodipine infused at a rate of 1.5 ccg/hg/min over a pertod of 10 minutes did not affect heart rate and kft ventrkutar end-diastdic pressure. The contractile responses during isovolumic contraction showed a slight but dgnificant increase in maximum vetocity (56 f 10 to 60 f 10 seconds-'; p <O.OOS), whereas the time constant of early relaxation was shortened from 49 f 11 to 44 f a ms (p <O.OS). Coronary stnus and great cardiac vein flow increased significantly by 15 and 2696, respecttvety. As mean aortic pressure decreased, a significant decrease in coronary shtus (-27%) and great cardiac vein (-28%) resistance was observed, white the calculated myocardial oxygen consumption remained unchanged. In all, 69 coronary segments (including 13 stenotic segments) were analyzed quantitatively using computer-asststed quantitative coronary angiography. A stgnificant imrease in mean coronary artery diameter (2.27 f OS3 to 2.46 f 0.53 mm; p <O.OOOOOl), as well as in obstruction diameter, (1.08 f 0.29 to 1.36 f 0.32 mm; p <0.02), was
benzyl)-amine)-ethyl, 2,6-dimethyl-4-(2',3'-methylenedioxypheynl)-1,4-dihydropyridine-3,5-dicarboxylate, monohydrochloride) is a newly synthesized drug with calcium entry blocking properties belonging to the second generation of the phenyldihydropyridine group.iy2 In vitro studies have shown that the drug ap pears to be loo-fold more potent in inducing vasodilatation than in causing negative inotropic effects' and that when comparing different vascular beds, the most pronounced vasodilatory effect was in the coronary vasculature. 3 This relative selectivity of elgodipine for the coronary vascular bed may be of particular significance in patients with coronary artery disease where an imbalance in myocardial oxygen supply and demand is caused by decrease in the coronary artery luminal diameter. Animal studies3,4 have demonstrated that elgodipine is a potent vasodilator, decreasing blood pressure and total peripheral resistance, and increasing cardiac output and coronary blood flow dose-dependently, with little effect on heart rate. The potency of elgodipine in reducing systemic vascular resistance is slightly leas than that of nifedipine, nisoldipine and nimodipine, but considerably greater (lO-to 50-fold) than that of bepridil, nicorandil and pimobendan.3 These effects of elgodipine on systemic and coronary hemodynamics have yet to be evaluated in patients with coronary artery disease. The present study investigates the effects of intravenous elgodipine on coronary and left ventricular hemodynamics, and assesses quantitatively the vasodilatory action of elgodipine on both stenotic and nonstenotic coronary arteries, using computer-assisted quantitative coronary angiography.
METHODS
Patknk The study comprised 15 patients (12 men and 3 women, mean age 57 years, range 40 to 69) who underwent cardiac catheterization for the investigation of suspected coronary artery disease. All patients were in sinus rhythm with no signs of cardiac failure and gave informed consent to participate in the study. Patients with unstable angina and acute myocardial infarction were excluded from the study. Clinical and angiographic data are listed in Table I .
Protecob All medication was discontinued 148 hours before the study. Cardiac catheterization was performed through the femoral artery and vein. Patients fasted and were not given premeditation. No drug (other than 50 mg of intravenous heparin) was administered during the study. After a thermodilution flow catheter was inserted in the coronary sinus and great cardiac vein, angiography of the right and left coronary artery 1  43F  II  0  70  0  0  +  2  66M  Ill  Anterior  49  +  +  +  3  68M  II  0  50  +  +  +  4  64M  I  Inferior  41  +  0  +  5  55M  II  0  62  0  +  0  6  63M  II  0  77  0  +  +  7  40M  II  Anterior  67  +  0  0  8  44M  II  Anterior  -+  0  0  9  60M  II  Inferior  -+  +  + was performed in standard views including cranial and caudal angulations. The geometry of the x-ray gantry, and the kilovolts and milliamperes of the x-ray generator were obtained and recorded on-line for each angiogram. A dual-tip micromanometer catheter was then positioned in the left ventricle. Ten minutes after catheter instrumentation, baseline left ventricular and aortic pressures, pressure-derived indexes of isovolumic contraction and relaxation, and thermodilution coronary sinus and great cardiac vein flows were measured on-line at spontaneous heart rate. Oxygen saturations were obtained simultaneously from the aorta, coronary sinus and great cardiac vein. Elgodipine was then administered intravenously at a rate of 1.5 pg/kg/min over a period of 10 minutes, and all measurements were repeated at 5 Left ventricular parameters were measured at spontaneous heart rate using the dual-tip micromanometer catheter, where 112 heart beats were processed and averaged on-line by means of the representative beat method in a dedicated computer system.5, 6 The following left ventricular pressure-derived indexes of isovolumic contraction and relaxation were computed: peak left ventricular pressure, end-diastolic pressure, peak first derivative of left ventricular pressure (dP/dt), peak left ventricular dP/dt/p from total pressure providing p >20 mm Hg (peak Vcn), dP/dt/p linearly extrapolated to 0 mm Hg (Vmax), and the time constants for early relaxation (Tau), a semilogarithmic biexponential fit of the left ventricular pressure decay characterized by 2 exponential time constants: Taul for the first 40 ms, and Tau2, the fit after the first 40 ms.7 Mean aortic pressure was determined by digital integration. spectrophotometrically, and oxygen content was calculated. Global (coronary sinus) and regional (great cardiac vein) myocardial oxygen consumptions were calculated as the product of coronary venous blood flow and arteriocoronary venous oxygen content difference. Global and regional coronary vascular resistances were derived from the ratio of mean aortic pressure to coronary venous flow.
Quantitative coronary angiography: Quantitative analysis of selected coronary segments was performed with the computer-assisted cardiovascular angiography analysis system that was described in detail previously-*v9 Briefly, to analyze a coronary arterial segment in a selected frame of 35 mm cinefilm, an optically magnified portion of the image encompassing that segment is converted into video format by means of a cinevideo converter. The contours of the vessels are detected auto matically on the basis of the weighted sum of first and second derivative functions applied to the digitized brightness information. Calibration of the diameter data of the vessels in absolute values (mm) is achieved using the angiographic catheter filmed empty of contrast. To this end, the contours of a user-defined portion of the optimally magnified catheter are detected automatically and corrected for pincushion distortion caused by the image intensifier. From the contours, vessel diameter functions (in absolute mm) are determined by computing the shortest distances between the left and right contour positions. A representative analysis with the detected contours and diameter functions superimposed on the original video image is shown in Figure 1 . For nonobstructed coronary segments, the mean diameter of the analyzed segment was computed. For obstructed segments, the minimal obstruction diameter was assessed. Average values for baseline, and lo-and 20-minute angiograms obtained from 12 orthogonal angiographic views were compared.
-ticai w--gradientstenotic lesionsr For obstructed coronary segments, the theoretical pressure gradients across the stenotic lesion at theoretical coronary flow rates of 1, 2 and 3 ml/s were calculated using the data obtained at quantitative angio graphic analysis according to an accepted formula'0Ji: Porno = Q -(Rp + Q * Rr), where Pox~n is the theoretical pressure reduction (mm Hg) across the stenosis, Q is the mean coronary blood flow (ml/s), Rp is the Poiseuille resistance, and R-r is the turbulent resistance. These resistances have been defined as follows:
where Ci = 8 X (blood viscosity), with blood viscosity = 0.03 (g/cm -s), and . This assessment of pressure gradients was used and described in our previous studies.i2-I4 Statirtieal analysis: Results are expressed as mean f SD. The data was subjected to analysis of variance for repeated measurements, and when significant differences were apparent, further comparisons were made with Student's paired t test. A p value <0.05 was considered significant.
RESULTS
Systemic hemdynamies: The systemic responses after intravenous administration of elgodipine at a rate of 1.5 rg/kg/min over 10 minutes are listed in Table II . At spontaneous heart rate, elgodipine produced a significant decrease in aortic pressure, while heart rate did not change significantly. During elgodipine infusion, left ventricular systolic pressure decreased significantly by 16% (p <O.OOOOS), while end-diastolic pressure remained unchanged (Table II) . Although the increase in peak Vca did not reach statistical significance, Vmax was significantly increased (56 f 10 to 60 f 10 seconds-'; p <O.OOS), whereas Taul was shortened (49 f 11 to 44 f 9 ms; p <0.05). At 20 minutes, all parameters were no longer significantly different from baseline.
Coronary hendynamics: After elgodipine infusion, coronary sinus and great cardiac vein blood flows increased significantly (75 f 26 to 86 f 30 ml/r&r [p . Although the differences in mean arteriocoronary sinus and arterio-great cardiac vein oxygen contents decreased from 13.9 f 1.7 to 11.9 f 1.5 ml% (p <0.00005) and from 13.9 f 1.7 to 12.0 f 1.5 ml% (p <0.0005), respectively, the global and regional myocardial oxygen consumptions remained unchanged. QwnWathrecoronary anglograms: In all, 69 coronary segments (including 13 stenotic segments) of the left coronary artery were analyzed. The individual changes in absolute diameter (mm) of all coronary segments as measured during the 3 consecutive angiograms are listed in Table IV . Mean coronary diameter increased significantly from 2.27 f 0.53 to 2.48 f 0.53 mm (p <O.OOOOOl) at 10 minutes and to 2.39 f 0.52 mm (p <O.OOOOOl) at 30 minutes after initiation of drug infusion.
Data for the 13 stenotic segments are listed in Table  V . Mean obstruction diameter increased significantly from 1.08 f 0.29 to 1.36 f 0.32 mm (p <0.02) at 10 minutes and to 1.26 f 0.33 mm (p <0.03) at 30 minutes after drug infusion was begun, whereas diameter stenosis decreased from 58 f 6 to 49 f 8% (p <0.008) and to 52 f 10% (p <0.05), respectively. Consequently, assuming theoretical coronary flows of 1, 2 and 3 ml/s, the theoretical pressure gradients across the 13 stenotic lesions decreased significantly after elgodipine infusion (Figure 2 ).
DISCUSSION
The results of this study of patients with coronary artery disease confirm for the first time the beneficial effects of elgodipine, a newly synthesized dihydropyridine calcium antagonist, on systemic and coronary he-ments.J*4
Meets on he& rate: Several studies in anesthetized animals3 showed that elgodipine is a potent systemic and coronary vasodilator, decreasing blood pressure and total peripheral resistance in a dose-dependent manner associated with an increase in coronary blood flow, whereas heart rate does not change or may even decrease in response to higher doses (60 pg/kg). Therefore, it is likely that (as observed with nimodipine)15 elgodipine possesses some negative chronotropic activity' that counteracts reflex tachycardia. However, it should be appreciated that reflex tachycardia can be attenuated by anesthetic agents, reducing thii phenomenon in anesthetized animals. To establish the cardiovascular profile of elgodipine, free of the potential influence of anesthetic agents, van Woerkens et al4 investigated its effects in conscious instrumented pigs and observed a marked increase in heart rate, as well as in cardiac output and dP/dtmax. Although large doses of elgodipine were used, this may suggest that anesthesia in earlier studies blunted a reflex-mediated tachycardia. However, despite anesthesia, nisoldipine increases heart rate at a dose producing an equivalent reduction in systemic pressure. 16 Furthermore, when elgodipine is administered to conscious pigs after /3-adrenoceptor blockade with propranolol, positive chronotropic and inotropic effects are substantially reduced, although an increase in heart rate is not completely eliminated4 This propranolol-resistant tachycardia is not unique to elgodipine, as it has also been observed for other dihydropyridines and vasodilators*7-22 and suggests a withdrawal of parasympathic tone. modynamics previously suggested by animal experi- _ 1 In the present study, despite a marked decrease in aortic pressure, only a slight increase in heart rate was (Table II) . Although all cardiac medication (including &blocking agents) was discontinued in all patients 148 hours before the study it may be speculated that @-adrenoceptor blockade could persist beyond this time and contributed to the lack of effect on heart rate. However, the resting heart rates of our study population suggest minimal B-blockade effect at the initiation of the study.
Effaets on inotropie state: In vitro studies have shown that elgodipine appears to be lOO-fold more po- Coronary artery segments tent as a vasodilator than as a negative inotrope.' In conscious animals, elgodipine produces dose-related increases in cardiac output and dP/dtmax, while left ventricular end-diastolic pressure (as with other dihydropyridines)i7 remains unchanged. 4 In conscious pigs with a 3-to 4-week-old myocardial infarction, the vasodilator responses to elgodipine are similar, although accompanied by considerably less of an increase in dP/dtmax compared with the effects in normal animals, but left ventricular end-diastolic pressure decreases signiticantly. 4 In the present study, elgodipine infusion led to a slight but significant increase in Vmax (Table II) . Because heart rate and left ventricular end-diastolic pressure were unaffected, it may be suggested that, as used in the present study, the compound does not exert negative inotropic actions. However, our approach using isovolumic indexes could not entirely exclude the possibility of some negative inotropism. Furthermore, because elgodipine does not possess any Badrenomimetic effects, this relatively positive inotropic response to the drug is probably not an intrinsic property of this new calcium antagonist, but rather related to its ability to induce peripheral vasodilation and reduce impedance to left ventricular ejection. However, the absence of a negative inotropic effect of elgodipine is even more evident during intracoronary infusion3; 0.3 pg/kg/min substantially dilated the coronary vascular bed, but had only a minor effect on regional contractile function, whereas negative inotropic effects only became apparent at a rate of 0.9 pg/ kg/mm, which also affected systemic responses. Administered intravenously, a 30-fold greater dose would be needed to produce a negative inotropic effect, almost 20 times the dose administered in our study. Realistically, such a dose would not be clinically appropriate, because of the likelihood of severe hypotension.
Effects on isovolumic relaxation:
Experimental work has emphasized the role of calcium influx-efflux in regulating the relaxation of the myocardial cell.23 Left ventricular isovolumic relaxation is often abnormally prolonged in patients with coronary artery disease,7.24.25 probably due to the presence of fibrotic scar tissue or still viable myocardium in which the biochemical process of activation (contraction and relaxation) has been altered by chronic ischemia. 25, 26 Because it has been demonstrated that myocardial ischemia leads to asynergy of wall motion that can have a major role in altering the time course of the isovohunic pressure reduction,26+27 it may be expected that an improvement of the asynergic zones would result in a more synchronous and rapid relaxation of the whole ventricle. In our study, Taul was significantly shortened after intravenous infusion of elgodipine (Table II) . However, these results do not necessarily imply the intrinsic improvement of relaxation, but may be the indirect effects of a significant decrease in end-systolic pressure and volume.
EffeCtSOIl eeswuuy vi: Animal work has shown that intravenous elgodipine dose-dependently increases myocardial blood flow, with the greatest increase (up to 30%) occurring in the subepicardial layer. 3 In the presence of a simultaneous decrease in perfusion pressure, vasodilatation occurs in all layers of the myocardium to produce the necessary decrease in coronary vascular resistance, the decrease in the subepicardium (45%) being more pronounced than that (30%) in the subendocardium.3 The present study confirms that elgodipine is a potent coronary vasodilator in humans. Coronary sinus and great cardiac vein flows increased significantly during elgodipine infusion by 15 and 26%, respectively. As mean aortic pressure dropped, substantial decreases in global (-27%) and regional (-28%) coronary vascular resistances were observed. The increase in coronary venous flow was associated with an increase in coronary venous oxygen saturation, resulting in a de crease in arteriocoronary venous oxygen content difference such that the calculated myocardial oxygen consumption did not decrease significantly (Table III) . These results are consistent with our previous study of the effects of intravenous nisoldipine.28 alantitathfe eoro~ry angiography: To increase the accuracy of diameter measurements and to better re fleet the true luminal cross-sectional area, multiple angiographic views (12 orthogonal) were obtained in our study. If a coronary segment is nonaxisymmetric, vasodilation may accentuate the asymmetry of the lumen by preferentially relaxing the nonatherosclerotic part of the arterial wall. Consequently, the use of 1 angiographic view would be misleading. A relatively limited number of stenotic lesions was analyzed in this study owing to the following: (1) Selection needed high technical quality angiograms with clear views of the pre-and poststa notic segments; (2) orthogonal projections of the stenotic lesions were necessary; and (3) repeated angiography was limited to the left coronary artery.
Our results indicate that elgodipine induces signilicant vasodilatation not only in normal but also in stenotic coronary segments (Tables IV and V) . The increase in the diameter of the nonstenotic segments was more pronounced in the distal and smaller sized segments than that in the larger proximal ones ( Figure  3) as was previously observed with other vasodilatory agents.29y30 Furthermore, the theoretical pressure gradients across the stenotic lesions (computed from the data obtained at quantitative coronary angiography) showed a considerable decrease after elgodipine administration (Figure 2 ).
Clinical implicetiens: At the dose used in the present study, elgodipine did not produce any untoward effects and was consistently beneficial in terms of coronary he modynamics. Therefore, elgodipine is of potential value for the treatment of ischemic heart disease and hypertension. Furthermore, the apparent absence of negative inotropic effects, and the reduction of cardiac afterload without an increase in preload are perhaps of particular relevance to the treatment of patients with mild to moderate congestive heart failure.
